Roche seeks Avastin cervical cancer indication

July 15, 2014 7:33 PM

7 0

Roche seeks Avastin cervical cancer indication

Roche scored the FDA's Priority Review label for its billion-dollar drug Avastin for use among patients with persistent, recurrent or metastatic cervical cancer, when paired with chemotherapy.

The Priority Review means the supplemental Biologics License Application request will get a speedier ride through the Food and Drug Administration's review process, based on the regulator's assessment that the drug treatment can provide a significant improvement in the safety and effectiveness over ...

Read more

To category page

Loading...